AbbVie (ABBV) sees further EPS expansion beyond the high single digit compound annual revenue growth forecast from 2024-2029

AbbVie is projecting further earnings per share (EPS) expansion, signaling strong underlying performance amidst a robust high single-digit revenue growth forecast from 2024 to 2029. This guidance reflects confidence in its pipeline and potential for sustainable profitability, which could boost sentiment toward its shares and have positive read-through effects for the biotech sector. Traders should consider how this outlook aligns with current market expectations and any implications for AbbVie’s stock relative to peers.